新诊断多发性骨髓瘤中按Deauville标准标准化18F-FDG-PET/CT定义代谢完全缓解
结果显示,治疗后局灶性病变和骨髓FDG摄取低于肝脏本底是PFS和OS改善的独立预测因素,可作为PET完全代谢缓解的标准化标准,证实Deauville评分在MM中的价值。
要点
- 治疗后局灶性病变FDG摄取低于肝脏本底与PFS和OS改善独立相关。
- 骨髓FDG摄取低于肝脏本底同样与PFS和OS改善独立相关。
- Deauville评分可用于多发性骨髓瘤PET完全代谢缓解的标准化定义。
核心结论
- 治疗后局灶性病变和骨髓FDG摄取低于肝脏本底是PFS和OS改善的独立预测因素。
- 该标准可被提议作为PET完全代谢缓解的标准化标准,证实Deauville评分的价值。
研究设计与样本
- 研究联合分析两项独立欧洲随机III期试验(IFM/DFCI2009和EMN02/HO95)中新诊断适合移植的多发性骨髓瘤患者。
- 按研究设计,在基线和开始维持治疗前进行PET/CT扫描。
- 采用五点Deauville量表描述骨髓和局灶性病变的摄取,并进行事后单变量和多变量分析。
主要发现
- 基线时78%患者有局灶性病变(11%髓外),其中80% FS≥4;所有患者均有骨髓弥漫性摄取(35.5% BMS≥4)。
- 维持治疗前,31%患者有肉眼可检测的局灶性病变(2%髓外),其中24% FS为3,67.7% FS≥4。
- 维持治疗前,98%患者保留残余骨髓弥漫性摄取,显著低于基线(主要介于BMS 2和3之间,仅8.7%患者BMS≥4)。
- 单变量和多变量分析显示,维持治疗前FS和BMS<4与PFS和OS延长相关(OS:HR分别为0.6和0.47;PFS:HR分别为0.36和0.24)。
临床怎么用
- 对于新诊断适合移植的多发性骨髓瘤患者,治疗后PET/CT可采用Deauville评分评估代谢缓解。
- 局灶性病变和骨髓FDG摄取低于肝脏本底可作为PET完全代谢缓解的标准化标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: 18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) is currently the standard technique to define minimal residual disease (MRD) status outside the bone marrow (BM) in patients with multiple myeloma (MM). This study aimed to define criteria for PET complete metabolic response after therapy, jointly analyzing a subgroup of newly diagnosed transplantation-eligible patients with MM enrolled in two independent European randomized phase III trials (IFM/DFCI2009 and EMN02/HO95). PATIENTS AND METHODS: Two hundred twenty-eight patients were observed for a median of 62.9 months. By study design, PET/CT scans were performed at baseline and before starting maintenance (premaintenance [PM]). The five-point Deauville scale (DS) was applied to describe BM (BM score [BMS]) and focal lesion (FL; FL score [FS]) uptake and tested a posteriori in uni- and multivariable analyses for their impact on clinical outcomes. RESULTS: At baseline, 78% of patients had FLs (11% extramedullary), 80% with an FS ≥ 4. All patients had BM diffuse uptake (35.5% with BMS ≥ 4). At PM, 31% of patients had visually detectable FLs (2% extramedullary), 24% and 67.7% of them with an FS of 3 and ≥ 4, respectively. At PM, 98% of patients retained residual BM diffuse uptake, which was significantly lower than at baseline (mainly between BMS 2 and 3, BMS was ≥ 4 in only 8.7% of patients). By both uni- and multivariable analysis, FS and BMS < 4 were associated with prolonged progression-free survival (PFS) and overall survival (OS) at PM (OS: hazard ratio [HR], 0.6 and 0.47, respectively; PFS: HR, 0.36 and 0.24, respectively). CONCLUSION: FL and BM FDG uptake lower than the liver background after therapy was an independent predictor for improved PFS and OS and can be proposed as the standardized criterion of PET complete metabolic response, confirming the value of the DS for patients with MM.
引用
- Zamagni E, Nanni C, Dozza L, et al. Standardization of 18F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma. J Clin Oncol. 2020. PMID: 33151787. doi:10.1200/JCO.20.00386
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。